Tokyo, Japan

Risa Nodera


Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2019-2021

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Risa Nodera: Innovator in Chondroitin Sulfate Derivatives

Introduction

Risa Nodera is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of biomedical materials, particularly through her work on chondroitin sulfate derivatives. With a total of 2 patents to her name, her innovations are paving the way for advancements in medical treatments.

Latest Patents

Risa Nodera's latest patents include a groundbreaking invention titled "Crosslinked chondroitin sulfate, composition containing same, and treatment agent for eye disease." This patent provides a chondroitin sulfate derivative that features a cross-linked structure through a group in a polyvalent amine. Additionally, the patent outlines a composition that includes this chondroitin sulfate derivative, along with an agent and method for treating eye diseases. The therapeutic effect of this invention targets corneal epithelial disorders and dry eye conditions.

Career Highlights

Risa Nodera is currently associated with Seikagaku Corporation, where she continues to innovate and develop new biomedical solutions. Her work is instrumental in enhancing the understanding and application of chondroitin sulfate in medical treatments.

Collaborations

Risa collaborates with notable colleagues, including Sho Funayama and Takahiro Hatanaka. These partnerships foster a creative environment that encourages the development of innovative solutions in the field of biomedical research.

Conclusion

Risa Nodera's contributions to the field of chondroitin sulfate derivatives exemplify her dedication to advancing medical science. Her patents not only highlight her innovative spirit but also promise to improve treatment options for eye diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…